Aptar Pharma's preservative-free multi-dose ophthalmic squeeze dispense launched in the US
First preservative-free multi-dose eye drop featuring Aptar Pharma’s OSD in the US.
Aptar Pharma has partnered with a leading eye care company to develop and launch a new eye drop product, which uses Aptar Pharma’s innovative preservative-free multi-dose Ophthalmic Squeeze Dispenser (OSD). This is the first preservative-free multi-dose eye drop featuring Aptar Pharma’s OSD in the US.
Following the worldwide trend towards safe, patient-friendly, cost-effective and preservative-free multi-dose dispensers such as Aptar Pharma's OSD system, the new over-the-counter (OTC) eye care product is able to maintain its status as the gold standard in lubricant eye drops.
The first OTC product marketed with OSD in the US
The newly released OTC eye drop product relieves dry, red, itchy eyes by providing preservative free eye drops in a revolutionary multi-dose bottle. Aptar Pharma has worked closely with a leading eye care company to improve patient safety, achieve dosing accuracy and maintain product integrity. The proprietary, sterile, lubricant eye drop formulation, contains 10 mL of solution, equivalent to more than 250 drops and claims to remain sterile for up to 3 months after first use. It is being supported by extensive television advertising and is available nationwide in pharmacies, supermarkets, and other retailers.
Meeting the needs of patients and consumers
Dry eye patients and consumers use lubricant eye drops on a regular basis, and often for the rest of their lives. It is well proven that preserved medications may cause unpleasant and sometimes serious side effects. Consequently, removing preservatives from the formulation by using Aptar Pharma’s OSD system is appreciated by the increasing number of patients and consumers experiencing eye irritation or allergic responses with preserved formulations.
Key benefits of Aptar Pharma’s OSD technology platform
Aptar Pharma’s OSD system is the result of more than 10 years of development for the delivery of preservative free ophthalmic solutions. European patients and consumers have benefited from this technology for years with more than 70 commercial references available on the market.
For the newly released over-the-counter product, Aptar Pharma’s OSD system delivers the following features:
· Unrivalled microbiological safety
· Intrinsic intuitiveness of a squeezable container
· User friendliness for all age groups due to a low actuation force
· Precise and reproducible drop ejection
· Ergonomic and pocket size design.
“The launch of Aptar Pharma’s OSD system in the US is a welcome event for patients suffering from eye irritations as it offers them significant benefits compared with standard therapy. This is also a very important milestone for Aptar Pharma in its international development strategy,” said Matthias Birkhoff, Vice President Business Development for Aptar Pharma’s Consumer Health Care Division.
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance